G01N 2333/96455
Kallikrein
Official title: Kallikrein (3.4.21.34; 3.4.21.35)
G01N2333/96455 (Kallikrein) appears on 180 US grants and 196 published applications in this corpus.
Search patents in G01N- Granted patents
- 180
- Published applications
- 196
- Assignees
- 108
- Inventors
- 344
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 3 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 4 | 0 |
| 1996 | 7 | 0 |
| 1997 | 20 | 0 |
| 1998 | 27 | 0 |
| 1999 | 7 | 0 |
| 2000 | 7 | 0 |
| 2001 | 8 | 0 |
| 2002 | 5 | 4 |
| 2003 | 4 | 11 |
| 2004 | 4 | 10 |
| 2005 | 2 | 4 |
| 2006 | 2 | 12 |
| 2007 | 1 | 6 |
| 2008 | 2 | 2 |
| 2009 | 2 | 5 |
| 2010 | 2 | 7 |
| 2011 | 3 | 6 |
| 2012 | 6 | 9 |
| 2013 | 1 | 9 |
| 2014 | 6 | 10 |
| 2015 | 3 | 6 |
| 2016 | 5 | 21 |
| 2017 | 4 | 11 |
| 2018 | 4 | 8 |
| 2019 | 7 | 9 |
| 2020 | 5 | 7 |
| 2021 | 2 | 3 |
| 2022 | 6 | 8 |
| 2023 | 2 | 8 |
| 2024 | 5 | 6 |
| 2025 | 5 | 8 |
| 2026 | 3 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Kits22 Sep 2026US 12,742,779 B1Takeda Pharmaceutical Company Limited
- Systems for providing a probability of prostate cancer risk and/or prostate gland volume, and related methods16 Jun 2026US 12,656,348 B2OPKO Diagnostics, LLC
- Nanopore assemblies and uses thereof26 May 2026US 12,638,452 B2Oxford Nanopore Technologies PLC
- Prostate antigen standards and uses thereof30 Dec 2025US 12,510,543 B2OPKO Diagnostics, LLC
- Assays for determining plasma kallikrein system biomarkers14 Oct 2025US 12,442,824 B2Takeda Pharmaceutical Company Limited
- Plasma kallikrein binding proteins2 Jul 2026US 2026/0184815 A1Takeda Pharmaceutical Company Limited
- Multiple biomarker for cancer diagnosis and use thereof26 Feb 2026US 2026/0055469 A1Maxion Corp.
- Therapeutic agents and uses thereof19 Feb 2026US 2026/0048159 A1Janssen Biotech, Inc.
- A pro-moiety for forming a prodrug selectively cleaved by prostate-specific antigen (psa)19 Feb 2026US 2026/0049102 A1
- Biomarkers8 Jan 2026US 2026/0009802 A1Oxford University Innovation Limited
Most cited
By later US patents
- Nucleic acid ligands561US 5,475,096 AUniversity Research Corporation · 1995
- Systematic evolution of ligands by exponential enrichment: Solution SELEX337US 5,567,588 AUniversity Research Corporation · 1996
- Systematic evolution of ligands by exponential enrichment: chimeric selex281US 5,637,459 ANeXstar Pharmaceuticals, Inc. · 1997
- High-affinity nucleic acid ligands that discriminate between theophylline and caffeine277US 5,580,737 ANeXstar Pharmaceuticals, Inc. · 1996
- Systematic evolution of ligands by exponential enrichment: blended SELEX233US 5,683,867 ANeXstar Pharmaceuticals, Inc. · 1997